Position in TEVA
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$322,103
+$19,710 QoQ
Shares Held
10,694
+10.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in TEVA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Arax Advisory Partners holds $1,784,999 across 41 Drug Manufacturers - Specialty & Generic names. TEVA ranks #2 (18.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
681 | $403,819 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
This page
|
10,694 | $322,103 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
1,432 | $188,651 | |
| 4 | ZTS |
Zoetis Inc.
|
1,527 | $180,506 | |
| 5 | VTRS |
Viatris Inc
|
10,932 | $147,691 | |
| 6 | TAK |
Takeda Pharmaceutical Co Ltd
|
4,343 | $80,432 | |
| 7 | ANIP |
Ani Pharmaceuticals Inc
|
1,030 | $79,207 | |
| 8 | ELAN |
Elanco Animal Health Inc
|
2,408 | $57,623 |
All Filings in TEVA
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $322,103 | 10,694 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $302,393 | 9,689 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $355,499 | 17,599 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $17,028 | 1,016 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $15,615 | 1,016 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $22,040 | 1,000 | Shares | Sole | 2025-02-05 | |
| 2024-09-30 | $18,020 | 1,000 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $16,250 | 1,000 | Shares | Sole | 2024-08-06 | |
| No filing history on record for this holder in this stock. | ||||||